Cost effectiveness of the type II Boston keratoprosthesis

PURPOSE: Despite demonstrated cost effectiveness, not all corneal disorders are amenable to type I Boston keratoprosthesis (KPro) implantation. This includes patients with autoimmune diseases, such as Stevens–Johnson syndrome/toxic epidermal necrolysis. Type II KPro is implanted through the eyelids...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ament, J D, Stryjewski, T P, Pujari, S, Siddique, S, Papaliodis, G N, Chodosh, J, Dohlman, C H
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2011
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3178310/
https://ncbi.nlm.nih.gov/pubmed/21183944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/eye.2010.197
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares